Advertisement
Table 1 SATB1-expression in relation to clinicopathological parameters and SATB2-expression
| Pancreatobiliary type | Intestinal type | |||||||
|---|---|---|---|---|---|---|---|---|
| SATB1 - n = 85 | SATB1 + n = 21 | SATB 1 missing n = 2 | p-value | SATB1- n = 47 | SATB1+ n = 16 | SATB1 missing n = 2 | p-value | |
| Age, years, M (IQR) | 66 (61–72) | 69 (64–74) | 2 | 0.681 | 67 (62–72) | 67 (57–70) | 2 | 0.981 |
| Sex, n (%) | 0.469 | 0.777 | ||||||
| Women | 41 (48%) | 8 (38%) | 2 | 26 (55%) | 8 (50%) | 1 | ||
| Men | 44 (52%) | 13 (62%) | 21 (45%) | 8 (50%) | 1 | |||
| Tumour origin, n (%) | 0.852 | 0.487 | ||||||
| Duodenum | 12 (26%) | 2 (13%) | ||||||
| Ampulla Intestinal type | 35 (74%) | 14 (87%) | 2 | |||||
| Ampulla Pancreatobiliary type | 16 (19%) | 3 (14%) | ||||||
| Distal bile duct | 34 (40%) | 10 (48%) | 1 | |||||
| Pancreas | 35 (41%) | 8 (38%) | 1 | |||||
| Tumour size, mm, M (IQR) | 30 (25–35) | 28 (21–30) | 2 | 0.799 | 25 (15–40) | 30 (24–40) | 2 | 0.848 |
| Differentiation grade, n (%) | 0.211 | 0.148 | ||||||
| Well-moderate | 34 (40%) | 5 (24%) | 1 | 26 (55%) | 5 (31%) | 1 | ||
| Poor | 51 (60%) | 16 (76%) | 1 | 21 (45%) | 11 (69%) | 1 | ||
| T-stage, n (%) | 1.000 | 0.860 | ||||||
| T1 | 2 (2%) | 0 | 1 | 4 (9%) | 0 | 1 | ||
| T2 | 8 (9%) | 2 (10%) | 8 (17%) | 3 (19%) | 1 | |||
| T3 | 61 (72%) | 16 (76%) | 1 | 18 (38%) | 7 (44%) | |||
| T4 | 14 (16%) | 3 (14%) | 17 (36%) | 6 (37%) | ||||
| N-stage, n (%) | 0.421 | 0.564 | ||||||
| N0 | 25 (29%) | 4 (19%) | 2 | 26 (55%) | 7 (44%) | 2 | ||
| N1-N2 | 60 (71%) | 17 (81%) | 21 (45%) | 9 (56%) | ||||
| Margins, n (%) | 1.000 | 1.000 | ||||||
| R0 | 5 (6%) | 1 (5%) | 1 | 13 (28%) | 4 (25%) | 1 | ||
| R1-Rx | 80 (94%) | 20 (95%) | 1 | 34 (72%) | 12 (75%) | 1 | ||
| Perineural growth, n (%) | 0.232 | 0.533 | ||||||
| No | 20 (24%) | 2 (10%) | 1 | 34 (72%) | 10 (62%) | 1 | ||
| Yes | 65 (76%) | 19 (90%) | 1 | 13 (28%) | 6 (38%) | 1 | ||
| Invasion of lymphatic vessels, n (%) | 0.792 | 0.081 | ||||||
| No | 25 (29%) | 7 (33%) | 1 | 25 (53%) | 4 (25%) | |||
| Yes | 60 (71%) | 14 (67%) | 1 | 22 (47%) | 12 (75%) | 2 | ||
| Invasion of blood vessels, n (%) | 0.070 | 0.594 | ||||||
| No | 60 (71%) | 10 (48%) | 1 | 44 (94%) | 14 (87%) | 2 | ||
| Yes | 25 (29%) | 11 (52%) | 1 | 3 (6%) | 2 (13%) | |||
| Growth in peripancreatic fat, n (%) | 0.760 | 0.545 | ||||||
| No | 18 (21%) | 3 (14%) | 2 | 32 (68%) | 9 (56%) | 2 | ||
| Yes | 67 (79%) | 18 (86%) | 15 (32%) | 7 (44%) | ||||
| SATB2, n (%) | 0.092 | 0.422 | ||||||
| Negative | 84 (99%) | 18 (90%) | 2 | 40 (89%) | 13 (81%) | 0 | ||
| Positive | 1 (1%) | 2 (10%) | 0 | 5 (11%) | 3 (19%) | 0 | ||
| Missing | 0 | 1 | 0 | 2 | 0 | 2 | ||
| Adjuvant chemotherapy, n (%) | 0.739 | 0.301 | ||||||
| No adjuvant | 41 (48%) | 9 (43%) | 1 | 35 (74%) | 10 (63%) | 2 | ||
| 5FU-analogue | 5 (6%) | 3 (14%) | 4 (9%) | 1 (6%) | ||||
| Gemcitabine | 35 (41%) | 9 (43%) | 5 (11%) | 2 (13%) | ||||
| Gemcitabine + capecitabine | 1 (1%) | 0 | 1 | 0 | 1 (6%) | |||
| Oxaliplatin +5-FU analogue | 1 (1%) | 0 | 3 (6%) | 1 (6%) | ||||
| Gemcitabine + oxaliplatin | 2 (2%) | 0 | 0 | 1 (6%) | ||||
| Recurrence | 0.250 | 0.658 | ||||||
| No | 16 (19%) | 3 (14%) | 1 | 27 (57%) | 7 (44%) | 1 | ||
| Yes, local only | 25 (29%) | 3 (14%) | 1 | 3 (6%) | 1 (6%) | |||
| Yes, non-local | 44 (52%) | 15 (71%) | 17 (36%) | 8 (50%) | 1 | |||
| Included in survival analyses | 1.000 | 1.000 | ||||||
| Yes | 84 (99%) | 21 (100%) | 0 | 45 (96%) | 16 (100%) | 0 | ||
| No | 1 (1%) | 0 | 2 | 2 (4%) | 0 | 2 | ||
